

**Fiscal Year 2012 (FY12) Tuberous Sclerosis Complex Research Program (TSCR)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-12-TSCR-CTA</p>	<p>Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Fund Phase 0, I, or II clinical trials relevant to TSC. Combinations of phases are permitted. • <i>Preliminary data required.</i> • Phase I or pilot clinical trial data required for Phase II clinical trial applications. 	<ul style="list-style-type: none"> • The maximum period of performance is 4 years. • The maximum allowable funding for the entire period of performance is \$1,000,000 in direct costs. • Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	<p>Pre-application (Letter of Intent): May 10, 2012 5:00 p.m. Eastern time (ET)</p> <p>Application: May 31, 2012 11:59 p.m. ET</p>
<p>Exploration – Hypothesis Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-12-TSCR-EHDA</p>	<p>Independent investigators, including junior faculty, including postdoctoral fellows (or equivalent).</p>	<ul style="list-style-type: none"> • Fund the initial exploration of innovative, untested research and pursue serendipitous observations. • <i>Preliminary data is encouraged but not required.</i> • Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 2 years. • The maximum allowable funding for the entire period of performance is \$100,000 in direct costs. • Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	<p>Pre-application (Letter of Intent): May 10, 2012 5:00 p.m. Eastern time (ET)</p> <p>Application: May 31, 2012 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: <u>W81XWH-12-TSCR-IDA</u></p>	<p>Principal Investigator: Must be an independent investigator with a documented faculty appointment (or equivalent).</p> <p>Optional Qualified Collaborator: Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p> <p>Optional Nested Postdoctoral Traineeship: Must have 3 years or less of postdoctoral experience at the time of application.</p>	<ul style="list-style-type: none"> • Encourage high impact, innovative research that will drive the field of TSC research forward. • <i>Preliminary data required.</i> • Optional Features: Applications that include either a Qualified Collaborator <i>or</i> Postdoctoral Fellow who meet criteria identified in the Program Announcement/Funding Opportunity may apply for a higher level of funding. • Clinical trials not allowed. 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$425,000 in direct costs (\$575,000 in direct costs if requesting an Optional Qualified Collaborator <i>or</i> Postdoctoral Fellow). • Indirect costs may be proposed in accordance with your institution's negotiated rate agreement. 	<p>Pre-application (Letter of Intent): May 10, 2012 5:00 p.m. Eastern time (ET)</p> <p>Application: May 31, 2012 11:59 p.m. ET</p>